Benzinga | Sep 15, 2020 08:20AM EDT

Alimera Sciences Signs Distribution Agreement With Medis Pharmaceutical To Commercialize Iluvien In Austria And Czech Republic

ATLANTA, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, has signed a distribution agreement with Medis Pharmaceutical Company d.o.o. (Medis) for the exclusive sales and distribution of ILUVIEN(r) in the Czech Republic and Austria. ILUVIEN is Alimera's sustained release intravitreal injection approved in these countries for both the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies and prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment (NIPU).

Medis will immediately assume responsibility for promotion, marketing and commercial activities in Austria where ILUVIEN is currently reimbursed. Additionally, Medis will commence negotiations in the Czech Republic with the State Institute for Drug Control regarding the appropriate public price and confidential net price for reimbursement of ILUVIEN in advance of the initiation of promotion, marketing and commercial activities.

"This agreement furthers Alimera's strategic objective to continue increasing the availability of ILUVIEN in additional European countries to treat patients suffering from both DME and NIPU," said Rick Eiswirth, President and Chief Executive Officer of Alimera. "Medis, with their strong growth and commitment to these markets, makes them a partner of choice, and we are pleased to be working with them as we expand the ILUVIEN franchise globally."

"We are extremely pleased to partner with Alimera to offer ILUVIEN to our customers in both Austria and the Czech Republic,"added Martina Perharic, Medis' Chief Executive Officer. "ILUVIEN's CONTINUOUS MICRODOSINGTM technology enables consistent treatment every day for up to three years to reduce the recurrence of disease, which we believe is highly important to physicians and the patients they serve."